Last €57.17 EUR
Change Today -0.82 / -1.41%
Volume 1.3K
LLY On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
Sao Paulo
EN Paris
Frankfurt
As of 3:17 PM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Open
€58.35
Previous Close
€57.99
Day High
€59.13
Day Low
€56.86
52 Week High
12/11/14 - €60.52
52 Week Low
01/3/14 - €36.98
Market Cap
63.7B
Average Volume 10 Days
1.4K
EPS TTM
--
Shares Outstanding
1.1B
EX-Date
02/11/15
P/E TM
--
Dividend
€2.00
Dividend Yield
2.58%
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency, as well as provides anti-infectives. Its neuroscience products treat major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and brain imaging of beta-amyloid neuritic plaques. The company’s oncology products treat pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as malignant pleural mesothelioma; and cardiovascular products are used to treat erectile dysfunction and benign prostatic hyperplasia, and pulmonary arterial hypertension, as well as to reduce thrombotic cardiovascular events and as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to enhance milk productivity in dairy cows; anticoccidial agents; and products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections. The company distributes its products through independent wholesale distributors and directly to pharmacies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

37,925 Employees
Last Reported Date: 02/19/14
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $680.7K
Senior Vice President and General Counsel
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2013.

eli lilly & co (LLY) Key Developments

Eli Lilly and Company Announces Five-Year Research Partnership with University of Surrey

Eli Lilly and Company announced a five-year research partnership with the University of Surrey to study health outcomes, focusing on the effects of treatment in people with type 2 diabetes, which affects about 95% of those with the disease. Using real-world evidence (routine data gathered from patients undergoing diabetes treatments), Lilly and the University of Surrey will focus on developing answers to commonly asked clinical questions about the continuum of diabetes care, such as the role and timing of injectable therapy, factors impacting adherence to prescribed medicines and the pattern and rationale of therapy following diagnosis. Initially the Lilly-Surrey collaboration will focus on some key questions: Adherence to therapy: Why do some people follow their diabetes treatment plan while others do not? What role do healthcare providers play in improving adherence rates? What are the barriers and the long-term effects for those who do not adhere to their treatment? Triggers for initiation of injectable therapy: People with type 2 diabetes often transition to different therapies in an effort to gain greater control of the disease. These transitions could include moving from an oral treatment to an injectable medicine, such as a glucagon-like peptide 1 receptor agonist (GLP-1) or insulin. Which treatment would be best? What factors influence a health-care professional's decision in choosing an injectable option? What factors influence the patient's acceptance of that decision? Understanding perspectives of both the patient and healthcare professional: How can health-care providers gain a better understanding of the patient's journey? What are the key questions they and the patient can ask each other? Can real-world perspectives increase understanding of why some patients accept transition from orals to injectables to insulin, while others are less enthusiastic?.

Eli Lilly and Company(NYSE:LLY) added to S&P 500 Growth Index

Eli Lilly and Company(NYSE:LLY) added to S&P 500 Growth Index

Douglas R. Oberhelman, Board Member of Eli Lilly and Company to Retire, Effective from May 4, 2015

On December 15, 2014, board member Douglas R. Oberhelman of Eli Lilly and Company announced that he has decided not to seek re-election to the board upon the expiration of his current three-year term of office on May 4, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:GR €57.17 EUR -0.82

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.85 USD +0.15
AbbVie Inc $66.98 USD +0.77
Actavis plc $257.09 USD +2.89
AstraZeneca PLC 4,556 GBp +39.00
Novo Nordisk A/S kr260.80 DKK -6.40
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 28.2x
Price/Sales 3.7x
Price/Book 4.3x
Price/Cash Flow 29.1x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.